Most Read News

The approval is valid for all Zydus Lifesciences affiliates and subsidiaries, said the company in the stock exchange filing dated March 10, 2025.

According to Jerome Powell, the Fed may pause on rates for now, and await clarity on Trump Tariffs

The NIFTY Pharma index closed the week with a 2.9% gain. Its performance was inline with that of NIFTY 50. In addition to a broadbased rally, strong performance from Biocon (+10.3%), Glenmark (+9.8%), and Laurus Labs (+8.3%) contributed to its performance. Concerns over tariffs from US on Indian pharmaceutical exports are the key headwind for the space. 

By leveraging advanced 3D printing and cutting-edge manufacturing techniques, we produce intricate yet lightweight pieces that appeal to today's consumers seeking both style and comfort. This focus allows us to offer premium products that are accessible to a broader audience, even amidst fluctuating gold prices.

The market correction was relatively subdued, but the good news is the positive bounce in mid-caps and small caps

IndusInd Bank is the only stock that hits a 52-week low in Sensex and Nifty

The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.

It was a relief rally in the first week of March, although the bounce was more pronounced in mid and small caps

FPIs net sold $(2,835) Million in Indian equities; marking one of the heavies weeks of FPI selling in recent months

Edelweiss Low Duration Fund is a smart saving fund, better than a bank account, but lower on risk than long duration debt